Key Points
- EVP Craig Hopkinson sold 5,000 shares on Jan. 8 at an average price of $30.00 for $150,000, leaving him with 61,740 shares (a 7.49% reduction in his stake).
- Alkermes beat expectations in its most recent quarter with $0.49 EPS vs. $0.41 expected and $394.19M revenue vs. $355.23M expected, and set FY2025 guidance of 1.360–1.470 EPS (analysts' average is ~1.31).
- The stock carries a consensus rating of "Moderate Buy" with an average target price of $44.69, and about 95.21% of shares are held by institutional investors (market cap ≈ $4.89B; recent open $29.60).
Alkermes plc (NASDAQ:ALKS - Get Free Report) EVP Craig Hopkinson sold 5,000 shares of the firm's stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the transaction, the executive vice president owned 61,740 shares in the company, valued at $1,852,200. The trade was a 7.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Alkermes Stock Up 0.8%
Shares of NASDAQ ALKS opened at $29.60 on Friday. Alkermes plc has a twelve month low of $25.17 and a twelve month high of $36.45. The firm has a market cap of $4.89 billion, a PE ratio of 14.65 and a beta of 0.48. The business has a fifty day simple moving average of $29.28 and a two-hundred day simple moving average of $29.05.
Alkermes (NASDAQ:ALKS - Get Free Report) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.41 by $0.08. The firm had revenue of $394.19 million for the quarter, compared to analyst estimates of $355.23 million. Alkermes had a return on equity of 21.81% and a net margin of 22.27%.The business's revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.73 earnings per share. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. On average, research analysts expect that Alkermes plc will post 1.31 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on ALKS shares. Zacks Research downgraded shares of Alkermes from a "strong-buy" rating to a "hold" rating in a research note on Thursday, November 20th. HC Wainwright reaffirmed a "neutral" rating on shares of Alkermes in a research report on Wednesday, October 22nd. Mizuho lifted their target price on Alkermes from $40.00 to $45.00 and gave the company an "outperform" rating in a research note on Monday, October 27th. Piper Sandler reiterated an "overweight" rating and issued a $45.00 target price (up from $38.00) on shares of Alkermes in a report on Thursday, October 23rd. Finally, Wall Street Zen cut shares of Alkermes from a "strong-buy" rating to a "buy" rating in a report on Sunday, November 9th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Alkermes has a consensus rating of "Moderate Buy" and an average target price of $44.69.
Check Out Our Latest Stock Analysis on ALKS
Hedge Funds Weigh In On Alkermes
Hedge funds and other institutional investors have recently modified their holdings of the stock. Baird Financial Group Inc. acquired a new position in Alkermes during the 1st quarter valued at approximately $587,000. Royal Bank of Canada increased its position in shares of Alkermes by 117.2% in the 1st quarter. Royal Bank of Canada now owns 275,526 shares of the company's stock valued at $9,098,000 after acquiring an additional 148,696 shares during the period. Advisors Asset Management Inc. lifted its position in Alkermes by 23.4% during the 1st quarter. Advisors Asset Management Inc. now owns 17,460 shares of the company's stock worth $577,000 after acquiring an additional 3,316 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Alkermes by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 102,885 shares of the company's stock valued at $3,399,000 after purchasing an additional 2,853 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC purchased a new stake in Alkermes during the 1st quarter valued at about $213,000. 95.21% of the stock is owned by hedge funds and other institutional investors.
Alkermes Company Profile
(
Get Free Report)
Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.
Alkermes' commercial franchise features several approved products.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
